Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Apr 2024
After having your eyes examined, you discovered that you require your first pair of glasses. Alternatively you realized that the pairs you currently own are insufficiently strong. When you wear them, everything appears incredibly clear. However, a few weeks later.
Read Full NewsA nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
1.
According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.
2.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
3.
Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
4.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
5.
A new blood test greatly increases the ability to detect cancer.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
4.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge